ponatinib - leitarniðurstöður

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

bosulif

pfizer europe ma eeig - bosutinib (ako monohydrát) - leukémia, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif je indikovaný na liečbu dospelých pacientov s:novo‑diagnostikovaná chronická fáza (cp) chromozóm philadelphia-pozitívne chronické myelogenous leukémia (ph+ cml). cp, zrýchlené fáza (ap), a odstreľovanie fáza (bp) ph+ cml predtým liečení jeden alebo viac tyrozín kinase inhibítor(s) [tki(y)] a pre koho imatinib, nilotinib a dasatinib nie sú považované za primerané možnosti liečby.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinálne stromálne nádory - antineoplastické činidlá - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

stivarga

bayer pharma ag - regorafenib - kolorektálne novotvary - antineoplastic agents, protein kinase inhibitors - stivarga je označené ako monotherapy na liečbu dospelých pacientov s metastatickým kolorektálnym (crc), ktorí boli v minulosti liečení, alebo nie sú považované za kandidátov na, k dispozícii terapie - tieto zahŕňajú fluoropyrimidine založené na chemoterapiu, anti-vegf terapia a anti-egfr terapia;unresectable alebo metastatickým gastrointestinálne stromal nádory (podstatu), ktorí postúpili na alebo netolerujú pred zaobchádzanie s imatinib a sunitinib;hepatocellular karcinóm (hcc), ktorí boli predtým liečení sorafenib.